Inhaled corticosteroids for the treatment of COVID-19
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 201...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2022-11-01
|
| Series: | European Respiratory Review |
| Online Access: | http://err.ersjournals.com/content/31/166/220099.full |
| _version_ | 1828071350355361792 |
|---|---|
| author | Mona Bafadhel Rosa Faner Camille Taillé Richard E.K. Russell Tobias Welte Peter J. Barnes Alvar Agustí |
| author_facet | Mona Bafadhel Rosa Faner Camille Taillé Richard E.K. Russell Tobias Welte Peter J. Barnes Alvar Agustí |
| author_sort | Mona Bafadhel |
| collection | DOAJ |
| description | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms. |
| first_indexed | 2024-04-11T00:53:06Z |
| format | Article |
| id | doaj.art-3f7aeb4e7ccd428f990e26821faa5098 |
| institution | Directory Open Access Journal |
| issn | 0905-9180 1600-0617 |
| language | English |
| last_indexed | 2024-04-11T00:53:06Z |
| publishDate | 2022-11-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | European Respiratory Review |
| spelling | doaj.art-3f7aeb4e7ccd428f990e26821faa50982023-01-05T07:48:22ZengEuropean Respiratory SocietyEuropean Respiratory Review0905-91801600-06172022-11-013116610.1183/16000617.0099-20220099-2022Inhaled corticosteroids for the treatment of COVID-19Mona Bafadhel0Rosa Faner1Camille Taillé2Richard E.K. Russell3Tobias Welte4Peter J. Barnes5Alvar Agustí6 King’s Centre for Lung Health, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UK CIBER Enfermedades Respiratorias, IDIBAPS, Barcelona, Spain Department of Pulmonary Diseases, University Hospital Bichat-Claude Bernard, AP-HP Nord, University of Paris, Paris, France King’s Centre for Lung Health, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UK Department of Pulmonary and Infectious Diseases, Hannover University School of Medicine, Hannover, Germany National Heart and Lung Institute, Imperial College London, London, UK Cátedra de Salud Respiratoria (University of Barcelona), Respiratory Institute (Hospital Clinic Barcelona), IDIBAPS and CIBERES, Barcelona, Spain The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms.http://err.ersjournals.com/content/31/166/220099.full |
| spellingShingle | Mona Bafadhel Rosa Faner Camille Taillé Richard E.K. Russell Tobias Welte Peter J. Barnes Alvar Agustí Inhaled corticosteroids for the treatment of COVID-19 European Respiratory Review |
| title | Inhaled corticosteroids for the treatment of COVID-19 |
| title_full | Inhaled corticosteroids for the treatment of COVID-19 |
| title_fullStr | Inhaled corticosteroids for the treatment of COVID-19 |
| title_full_unstemmed | Inhaled corticosteroids for the treatment of COVID-19 |
| title_short | Inhaled corticosteroids for the treatment of COVID-19 |
| title_sort | inhaled corticosteroids for the treatment of covid 19 |
| url | http://err.ersjournals.com/content/31/166/220099.full |
| work_keys_str_mv | AT monabafadhel inhaledcorticosteroidsforthetreatmentofcovid19 AT rosafaner inhaledcorticosteroidsforthetreatmentofcovid19 AT camilletaille inhaledcorticosteroidsforthetreatmentofcovid19 AT richardekrussell inhaledcorticosteroidsforthetreatmentofcovid19 AT tobiaswelte inhaledcorticosteroidsforthetreatmentofcovid19 AT peterjbarnes inhaledcorticosteroidsforthetreatmentofcovid19 AT alvaragusti inhaledcorticosteroidsforthetreatmentofcovid19 |